GLP-1 Peptides Explained: Semaglutide vs. Tirzepatide vs. Retatrutide (Research Guide)

For research and educational purposes only. Not medical advice.

Three peptides are reshaping how medicine thinks about obesity, metabolic disease, and body composition. Semaglutide opened the door. Tirzepatide blew it off the hinges. Retatrutide is building an entirely different house.

If readers have been following the biohacking and peptide research space over the past three years, they have watched GLP-1 receptor agonists go from a diabetes management tool to the most talked-about class of compounds in modern medicine. The search volume is extraordinary. The clinical results are extraordinary. And the confusion about what each compound actually is, how they differ mechanistically, what the trials actually showed, and where research peptides fit versus FDA-approved drugs is equally extraordinary. This guide cuts through all of it.

How GLP-1 and Related Agonist Peptides Actually Work

The listed research text specifies starting with the biology because without it, the differences between these three compounds make no sense.

GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone, meaning it is produced in the gut in response to food intake and signals to the rest of the body that nutrients have arrived. Its natural job is to stimulate insulin secretion from the pancreas in proportion to blood glucose levels, suppress glucagon release to prevent the liver from dumping more glucose into circulation, slow gastric emptying to extend the satiety window after a meal, and act on appetite regulatory centers in the brain (primarily the hypothalamus) to reduce hunger signals.

When researchers developed synthetic analogs that mimic and extend GLP-1 activity, they produced compounds that could sustain these effects for hours to days rather than the minutes that natural GLP-1 lasts before enzymes degrade it. The result was a class of drugs with genuinely novel mechanisms for metabolic disease management.

GIP stands for glucose-dependent insulinotropic polypeptide. Like GLP-1 it is an incretin hormone, but it operates through a distinct receptor and has historically been considered less important than GLP-1 for glucose management. That assessment changed when researchers discovered that combining GIP and GLP-1 receptor agonism produced metabolic effects significantly greater than either mechanism alone. The reasons why are not fully characterized but likely involve complementary effects on adipose tissue metabolism, pancreatic beta-cell function, and hypothalamic appetite signaling pathways.

Glucagon is the hormone that does the opposite of insulin. It signals the liver to release stored glucose and drives energy expenditure and fat breakdown. Activating the glucagon receptor while simultaneously activating GLP-1 and GIP creates a metabolic environment where appetite is suppressed, insulin response is optimized, and the body is simultaneously pushed toward burning fat for energy. This triple-agonist approach is the mechanistic innovation that distinguishes retatrutide from its predecessors.

Understanding these three receptor systems is the foundation for understanding why the clinical results look the way they do.

Semaglutide: The Compound That Started the Mainstream Conversation

Semaglutide is a once-weekly injectable GLP-1 receptor agonist developed by Novo Nordisk. It is approved as Ozempic for type 2 diabetes management and as Wegovy for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity. An oral tablet formulation is approved as Rybelsus for type 2 diabetes.

The STEP trial program established semaglutide's clinical evidence base for weight management. STEP-1, the landmark obesity trial, enrolled 1,961 adults without diabetes and documented mean weight reduction of approximately 14.9 percent from baseline over 68 weeks at the 2.4 mg weekly injectable dose, compared to 2.4 percent for placebo. At the time of publication in the New England Journal of Medicine in 2021, this was the largest average weight reduction ever documented in a major pharmaceutical obesity trial.

The SELECT cardiovascular outcomes trial, published in 2023, established something more significant for the broader research community than the weight loss numbers alone. The SELECT trial enrolled 17,604 adults with pre-existing cardiovascular disease and overweight or obesity without diabetes; over approximately 34 months, it showed that semaglutide reduced major adverse cardiovascular events by 20 percent. This was the first demonstration that a GLP-1 receptor agonist could reduce cardiovascular event risk in a non-diabetic population: a finding that substantially expanded the clinical significance of the compound class beyond metabolic endpoints.

Emerging 2025 and 2026 research has further expanded the evidence base into non-alcoholic steatohepatitis, chronic kidney disease, and early neurological signals for Parkinson's disease and Alzheimer's disease, where GLP-1 receptor expression in the brain has generated significant interest in the neuroprotective potential of this compound class.

The compounding access context: throughout 2024 and early 2025, FDA shortage designations allowed 503B outsourcing facilities to legally compound semaglutide at scale, creating a parallel supply chain that significantly expanded access. In April 2026, FDA published a proposed rule to formally exclude semaglutide from the 503B Bulk Drug Substances List. If finalized, this would prohibit 503B outsourcing facilities from compounding semaglutide regardless of market conditions. The 503A compounding pathway for patient-specific prescriptions from licensed pharmacies remains separately governed and continues under existing regulatory frameworks.

Tirzepatide: The Dual Agonist That Reset the Benchmark

Tirzepatide is a once-weekly injectable dual agonist targeting both the GIP receptor and the GLP-1 receptor simultaneously. It is developed by Eli Lilly and approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management.

The SURMOUNT trial program established tirzepatide's weight management evidence base. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight and at least one comorbidity and documented mean weight reduction of 15.0 percent at the 5 mg dose, 19.5 percent at 10 mg, and 20.9 percent at 15 mg, against 3.1 percent for placebo over 72 weeks. The 20.9 percent figure at maximum dose represented the highest average weight reduction ever documented in a major pharmaceutical obesity trial at that time.

Then SURMOUNT-5 moved the conversation forward in 2025. This was the first head-to-head randomized trial directly comparing tirzepatide against semaglutide at their respective maximum approved doses in the same population. The result was not close: approximately 20.2 percent mean weight reduction with tirzepatide versus approximately 13.7 percent with semaglutide over 72 weeks. Post-hoc analyses from SURMOUNT-5 data published in 2025 showed tirzepatide also produced greater improvements across multiple cardiometabolic risk markers, including blood pressure, lipid profiles, and inflammatory markers.

The mechanism behind tirzepatide's efficacy advantage is the GIP receptor component. Adding GIP agonism to GLP-1 agonism produces complementary effects on fat tissue metabolism, pancreatic beta-cell function, and hypothalamic appetite signaling that appear to be additive in ways that pure GLP-1 agonism cannot fully replicate. The specific contribution of each receptor system to the overall clinical effect has been a major focus of research in 2025 and 2026.

In plain terms: tirzepatide at maximum dose produces roughly 20 percent average body weight reduction over 72 weeks, outperforms semaglutide head-to-head in a direct comparison trial, and produces greater cardiometabolic improvements across multiple risk markers. It is the most effective approved metabolic drug in history at the time of this writing.

Retatrutide: The Triple Agonist With Surgical Weight Loss Numbers

Retatrutide is a once-weekly injectable triple agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously. As of July 2026, it is not FDA-approved and remains investigational under Eli Lilly's TRIUMPH Phase 3 clinical program. It is the most clinically significant unapproved compound in the metabolic medicine pipeline.

The Phase 2 data, published in the New England Journal of Medicine in 2023, produced numbers that reshaped the entire conversation about what a pharmaceutical compound could achieve for obesity treatment. The 12 mg weekly dose group achieved approximately 24.2 percent mean weight reduction at 48 weeks, a figure previously associated with bariatric surgery, not a pharmaceutical intervention.

The Phase 3 program has now delivered multiple readouts that confirm and exceed the Phase 2 findings.

TRIUMPH-4, reported in December 2025, enrolled adults with obesity and knee osteoarthritis. Participants on the 12 mg dose achieved 28.7 percent average weight loss at 68 weeks: approximately 71.2 pounds. Over 75 percent of participants experienced significant reduction in knee pain scores, with approximately one in eight becoming entirely pain-free.

TRIUMPH-1, the pivotal obesity trial, reported topline results on May 21, 2026. In 2,339 participants, retatrutide at 12 mg achieved 28.3 percent mean weight loss at 80 weeks. This figure is consistent with bariatric surgery outcomes and represents the highest weight reduction ever documented in a large-scale pharmaceutical trial.

TRANSCEND-T2D-1, a diabetes-specific trial, reported topline results in March 2026 and was published in The Lancet in June 2026. In 537 patients with type 2 diabetes, retatrutide produced a 2.0 percent reduction in HbA1c and 16.8 percent weight loss, demonstrating efficacy across the metabolic disease spectrum beyond obesity alone.

A nested sleep apnea substudy from TRIUMPH-1, presented at the ADA Scientific Sessions on June 6, 2026, showed a 60.6 percent reduction in the apnea-hypopnea index from a severe baseline of 58.6 events per hour (a clinically meaningful improvement in a condition affecting tens of millions of Americans).

One safety signal that emerged from TRIUMPH-4 requires attention: approximately 20.9 percent of patients on the highest dose reported dysesthesia (an abnormal skin sensation including tingling, numbness, or burning). This is a novel safety signal not previously associated with GLP-1 class compounds and is being characterized across the broader TRIUMPH program.

Where Research Peptides Fit Versus FDA-Approved Drugs

Semaglutide and tirzepatide are FDA-approved pharmaceutical drugs. They exist in a defined regulatory framework with approved indications, approved doses, approved manufacturing standards, post-market surveillance requirements, and prescribing physician accountability. When readers access these compounds through a licensed physician and a licensed pharmacy, they have a documented chain of custody, quality assurance from cGMP-regulated manufacturing, and a prescriber who is accountable for the care.

Retatrutide is not approved. It is an investigational compound available only through clinical trial enrollment through legitimate channels, or through the gray market via research-use-only vendors and some compounding pharmacies operating in regulatory gray areas.

The gray market access question is where the research peptide community intersects with this compound class in ways that require plain language rather than euphemism. Research-use-only retatrutide is available from vendors operating outside the pharmaceutical framework. The quality of those products varies enormously. The same mislabeling and contamination risks documented for research peptides broadly apply here. A compound this pharmacologically active at this dose range requires verified identity and purity confirmation before any research application.

This is precisely why the RUO Codes vendor vetting standard exists. Third-party identification testing, purity verification, endotoxin documentation, and sterility confirmation are not optional quality considerations for this compound class. They are the minimum acceptable standard. A COA from a named independent laboratory with mass spectrometry identification is what separates a verified research compound from an educated guess about what is in the vial.

For semaglutide and tirzepatide specifically, the compounding pharmacy landscape is the other access channel. The full regulatory framework governing compounding access for these compounds is covered in the 503A vs. 503B guide on RUO Codes.

The Side-by-Side Comparison: What the Numbers Actually Mean

The Bottom Line for Researchers

The GLP-1 compound class represents the most clinically significant advance in metabolic medicine in decades. The three compounds are not interchangeable. They represent sequential generations of mechanistic sophistication: single agonist, dual agonist, triple agonist, with each generation producing meaningfully greater clinical effects than the previous one.

The regulatory status of each compound determines how it can be legally accessed and what quality assurance attaches to that access. Semaglutide and tirzepatide are approved drugs available through physicians and pharmacies. Retatrutide is investigational, available through clinical trials officially and through research channels unofficially, with all the quality verification responsibilities that gray market sourcing entails.

For anyone navigating this landscape, the vendor quality question is not separate from the compound science question. It is part of the same decision. Knowing what retatrutide does in a Phase 3 trial matters. Knowing whether what is in the vial readers ordered is actually retatrutide at the stated dose and purity matters equally.

For vetted vendors carrying research compounds in the GLP-1 adjacent space with documented third-party COA verification, current coupon codes, and active sale information, visit RUO Codes/vendors.

For research and educational purposes only. Not medical advice. Regulatory status of specific compounds may change. Every protocol involving these compounds requires consultation with a qualified healthcare professional before initiation.

For the manufacturing and investment context behind growing GLP-1 capacity, read our analysis of Samsung Biologics' $1.8 billion PolyPeptide acquisition.

Related peptide litigation coverage

Peptide Company Lawsuits 2026: A New Wave Lands and the RUO Industry Braces for Impact — October 8 coverage from the RUO Codes Research Desk.

Compare the GLP-1 Research Evidence

For the receptor mechanisms, direct SURMOUNT-5 comparison, retatrutide trial context, safety signals and testing-documentation limits, read Semaglutide vs Tirzepatide vs Retatrutide Research Compared.